Omeprazol Actavis (Omeprazole)

Omeprazole acts on the gastric proton pump to manage several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.
• NSAID‑induced gastropathy: helps prevent ulcer formation in patients requiring long‑term NSAID therapy.

• Omeprazole selectively and irreversibly inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid secretion, it markedly lowers gastric acidity, allowing mucosal healing and symptom relief in acid‑related disorders.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild, transient headache reported in many patients.
• Diarrhea: loose stools that usually resolve without intervention.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach region.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis linked to altered gut flora.
• Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.
• Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmias.
• Stevens‑Johnson syndrome: rare skin reaction with blistering and mucosal involvement.
• Liver enzyme elevation: increased ALT/AST indicating hepatic stress.
• Fracture risk: long‑term use associated with reduced bone mineral density.

Before initiating therapy, consider the following safety measures:

• Assess renal function: adjust use in severe renal impairment.
• Evaluate hepatic status: use with caution in moderate liver disease.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor long‑term use: assess need for periodic vitamin B12 and magnesium testing.
• Pregnancy and lactation: weigh benefits against potential risks.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular event risk.
• Atazanavir: decreased absorption leading to loss of antiviral efficacy.
• Dasatinib: lowered plasma concentrations, potentially reducing therapeutic effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring more frequent monitoring.
• Phenytoin: reduced serum levels, may necessitate dose adjustment.
• Methotrexate: increased exposure, especially at high doses, requiring vigilance.
• Digoxin: modest rise in serum concentration, monitor for toxicity signs.